September 10, 2019 / 10:28 PM / a month ago

CORRECTED: GSK loses bid to overturn $89.7 mln verdict based on lawyer's statements at trial

(Corrects headline to $89.7 million instead of billion.)

A federal judge has rejected GlaxoSmithKline PLC’s bid to overturn an $89.7 million verdict after a jury found its Ellipta inhaler infringed a patent belonging to rival drug company Vectura Ltd.

U.S. District Judge Richard Andrews in Delaware ruled Tuesday that statements by Vectura’s lawyer during a trial about GSK’s “billions” in revenue were not so prejudicial as to warrant a new trial.

To read the full story on WestlawNext Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below